CorMedix (NYSEAMERICAN:CRMD) Stock Price Up 8.3%

CorMedix Inc. (NYSEAMERICAN:CRMD) rose 8.3% during mid-day trading on Wednesday . The stock traded as high as $9.38 and last traded at $8.99, approximately 597,839 shares traded hands during mid-day trading. An increase of 13% from the average daily volume of 530,322 shares. The stock had previously closed at $8.30.

A number of equities analysts have recently weighed in on CRMD shares. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Tuesday. HC Wainwright set a $55.00 price objective on shares of Acer Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 28th.

CorMedix (NYSEAMERICAN:CRMD) last announced its earnings results on Monday, May 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.07. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.06 million.

In other CorMedix news, Director Janet Dillione bought 11,144 shares of the stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $6.74 per share, for a total transaction of $75,110.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in CorMedix by 374.4% during the 4th quarter. BlackRock Inc. now owns 2,656,672 shares of the biotechnology company’s stock valued at $3,427,000 after buying an additional 2,096,663 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in CorMedix by 300.1% during the 4th quarter. Bank of New York Mellon Corp now owns 150,689 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 113,029 shares in the last quarter. EAM Global Investors LLC acquired a new stake in CorMedix during the 1st quarter valued at $940,000. Geode Capital Management LLC grew its holdings in CorMedix by 13.4% during the 4th quarter. Geode Capital Management LLC now owns 687,593 shares of the biotechnology company’s stock valued at $886,000 after purchasing an additional 81,136 shares in the last quarter. Finally, Tibra Equities Europe Ltd acquired a new stake in CorMedix during the 1st quarter valued at $593,000.

CorMedix Company Profile (NYSEAMERICAN:CRMD)

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Recommended Story: Investing strategies using the yield curve

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.